Mini Review

Induce Mesenchymal Stem Cells Differentiation into Insulin-Producing Cells: Mini-Review

Hongxin Lang¹, and Xiaohang Li²*

¹Department of Stem Cells and Regenerative Medicine, China Medical University, China

²Department of Hepatobiliary Surgery, China Medical University, China

Submission:April 19, 2022; Published:April 25, 2022

*Corresponding author:Xiaohang Li, Department of Hepatobiliary Surgery, First Affiliated Hospital, China Medical University, No.155, Nanjing North Street, Shenyang, 110001 Liaoning Province, China

How to cite this article: Hongxin L, Xiaohang L. Induce Mesenchymal Stem Cells Differentiation into Insulin-Producing Cells: Mini-Review. Adv Res Gastroentero Hepatol, 2022; 18(4): 555994. DOI: 10.19080/ARGH.2022.18.555994.

Abstract

Islet transplantation is an ideal treatment to cure diabetes. As shortage of donors is an insurmountable obstacle, the generation of insulin-producing cells to replace islet cell may be a promising approach. Mesenchymal stem cells (MSCs) that possesses great differentiation potential to other types of cells become an attractive source for generation of insulin-producing cells (IPCs). Many methods such as gene transfection and gene editing were used to induce MSCs differentiation into insulin-producing cells. We review the new progress in this field, advantages and drawbacks of insulin-producing cells in clinical application.

Keywords:Mesenchymal stem cell; Insulin-producing cells; islet; Diabetes

Abbreviations:DM: Diabetes Mellitus; T1DM: Type 1 Diabetes Mellitus; MSCs: Mesenchymal Stem Cells; IPCs: Insulin-Producing Cells

Mini Review

Diabetes mellitus (DM) is a global health concern with about 300 million individuals worldwide. The number of people suffered from DM may increase to more than 600 million by 2045 [1]. Type 1 diabetes mellitus (T1DM) patients, whose islets are destroyed by an autoimmune-mediated response, account for 5% of all diabetic patients. However, the existent treatments for the diabetes have kinds of drawbacks. Traditional exogenous insulin injections could maintain blood glucose level, but it could not reverse the chronic complications of diabetes, and there is a risk of hypoglycemia, which sometimes is lethal. Pancreatic transplantation may cure diabetes, but severe surgical trauma and life-long oral immunosuppressive drugs limit the use of pancreatic transplantation. Islet transplantation is an alternative treatment since it’s less invasive. However, the implementation of islet transplantation is also limited by limited islet availability and immune rejection. Mesenchymal stem cells (MSCs)-based therapy for T1DM has been the focus of many research over the past several decades. MSCs could be obtained from many types of tissue, including the bone marrow, fetal annexes, adipose tissue, dental tissues, skeletal muscle tissue, liver tissue, lung tissue, menstrual blood and pancreatic tissue [2-8]. The application of MSCs with the advantages of wide availability, negligible teratogenic risks,nonimmunogenic, differentiation potential to islet-like cell and immunoregulation may provide more competitive treatments comparing with other ones [9,10]. Therefore, MSCs are a promising option for therapy for T1DM.

Many literatures have reported that MSCs could be induced differentiation into insulin producing cells (IPCs). Tan found that pancreatic MSCs could differentiate into IPCs by the two-step induction method [11]. Zhang considered that pancreatic MSCs could be functionally induced into IPCs with the optimized three‑step protocol [12]. Both Zhang & Gabr [13,14] reported that bone marrow‑derived MSCs were differentiated into IPCs. Adipose tissue‑derived MSCs could also be differentiated into IPCs [15,16]. Van and Tasi found that IPCs differentiated from umbilical cord blood‑derived MSCs could treat streptozotocin‑induced diabetic rats [17,18]. The methods of inducing MSCs differentiation into IPCs include the following: firstly, gene transfection or gene editing. The most commonly used genes such as pancreatic and duodenal homeobox 1 (Pdx1), neuronal differentiation 1 (Neurod1) and Mafa were transfected into MSCs singly or in combination by plasmid or vector [19-21]. These genes play a crucial role in pancreatic organogenesis and β cell function. The other genes such as neurogenin-3 (NGN3) and paired box 4 (PAX4) are also key for differentiation and maturation of islet cells [22,23]. Thi Do transfected porcine bone marrow derived MSCs with the insulin gene and generated IPCs which can improve hyperglycemia in streptozotocin-diabetic pig [24].

Recently many researchers pay more attention to microRNAs (miRNAs) which also play vital roles in the generation of IPCs from stem cells. Because miR-375, which is specific and most abundant miRNA in islets, contributes to the development of β cells [25], many researchers attach more importance to it. Jafarian reported that IPCs were generated from bone marrow derived MSCs by transfection with both miR-375 and antimiR- 9 [26]. Bai et al. [27] induced umbilical cord derived MSCs differentiation into IPCs by transfection with miR-375 and miR- 26a. Zhao discovered a novel mouse miRNA which significantly promoted the differentiation of bone marrow derived MSCs into IPCs in vitro [28]. The breakthrough in genome editing makes it possible to induce endogenous human insulin transcription using the dCas9-VP160 transcriptional activator in human cells [29]. The CRISPR/Cas9 gene editing system identified the role of several transcription factors involved in pancreatic embryonic development [30], such as PDX1 and PTF1A, which are associated with several deficiencies in pancreatic agenesis. Secondly, directed differentiation. Currently, differentiation of stem cells into IPCs in vitro is being done using specific culture protocols. Generally speaking, cells were cultured in glucose-rich media with different growth and activation factors, which imitate the microenvironment in vivo for islet cell differentiation [31]. Gabr provided a 3-step differentiation protocol for inducing hBMMSCs differentiation into IPCs [14]. Ikemoto developed a simple protocol for differentiating IPCs from adipose derived MSCs with a 2-step protocol [32]. Three-dimensional (3D) culture is thought to better mimic the in vivo microenvironment, so Takeuchi and Khorsandi employed 3D culture to improve bone marrow/ adipose derived MSCs differentiation into IPCs [16,33]. Although great achievements have been obtained in this field, there are still some drawbacks. Firstly, the use of viral vectors faces risk of oncogene transactivation and spreading virus to human during clinical translation. The application of gene editing to human also faces huge ethical challenges. Secondly, directed differentiation protocols that induce MSCs to generate IPCs in vitro are expensive, difficult, time-consuming and less efficient. Thirdly, although the generated IPCs could reverse hyperglycemia in streptozotocindiabetic animals, they may be destroyed by the existing antibodies that have damaged the native β cells in T1DM after transplantation and could not function anymore.

Conclusion

In summary, there is still a long way to go before differentiated IPCs from MSCs could be transplanted to human. The MSCsderived IPCs should be able to control blood glucose level and should not be suspected of being teratogenic and tumorigenic,and they should avoid the damage by the antibodies in transplant recipients and function for a long time. Only when these standards are met, MSC-derived IPCs may be used in clinical practice on a large scale.

Acknowledgements

This study was supported by the Natural Science Foundation of Liaoning Province (2021-MS-177).

References

1. MA Ghoneim, AF Refaie, BL Elbassiouny, MM Gabr, MM Zakaria (2020) From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Progress and Challenges. Stem Cell Rev Rep 16(6): 1156-1172.
2. S Lee, S Moon, JY Oh, EH Seo, YH Kim, et al. (2019) Enhanced insulin production and reprogramming efficiency of mesenchymal stem cells derived from porcine pancreas using suitable induction medium. Xenotransplantation 26(1): e12451.
3. FG Teixeira, KM Panchalingam, SI Anjo, B Manadas, R Pereira, et al. (2015) Do hypoxia/normoxia culturing conditions change the neuroregulatory profile of Wharton Jelly mesenchymal stem cell secretome? Stem Cell Res Ther 6(1): 133.
4. AH Kisiel, LA McDuffee, E Masaoud, TR Bailey, BP Esparza, et al. (2012) Isolation, characterization, and in vitro proliferation of canine mesenchymal stem cells derived from bone marrow, adipose tissue, muscle, and periosteum. Am J Vet Res 73(8): 1305-1317.
5. KM Mrozik, PS Zilm, CJ Bagley, S Hack, P Hoffmann, et al. (2010) Proteomic characterization of mesenchymal stem cell-like populations derived from ovine periodontal ligament, dental pulp, and bone marrow: analysis of differentially expressed proteins. Stem Cells Dev 19(10): 1485-1499.
6. M Najimi, S Berardis, H El-Kehdy, V Rosseels, J Evraerts, et al. (2017) Human liver mesenchymal stem/progenitor cells inhibit hepatic stellate cell activation: in vitro and in vivo evaluation, Stem Cell Res Ther 8(1): 131.
7. TM Nordgren, KL Bailey, AJ Heires, D Katafiasz, DJ Romberger (2018) Effects of Agricultural Organic Dusts on Human Lung-Resident Mesenchymal Stem (Stromal) Cell Function. Toxicol Sci 162(2): 635-644.
8. D Ulrich, R Muralitharan, CE Gargett (2013) Toward the use of endometrial and menstrual blood mesenchymal stem cells for cell-based therapies. Expert Opin Biol Ther 13(10): 1387-1400.
9. AF Refaie, BL Elbassiouny, M Kloc, OM Sabek, SM Khater, et al. (2021) From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations. Front Immunol 12: 690623.
10. Y Shi, Y Wang, Q Li, K Liu, J Hou, et al. (2018) Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 14(8): 493-507.
11. J Tan, LP Liu, BY Li, Q Xie, JW Sun, et al. (2019) Pancreatic stem cells differentiate into insulin-secreting cells on fibroblast-modified PLGA membranes. Mat Sci Eng C-Mater 97: 593-601.
12. S Zhang, Q Wang, H Ji, H Lu, Q Yang, et al. (2021) Porcine pancreas mesenchymal cell characterization and functional differentiation into insulin producing cells in vitro. Mol Med Rep 24(4): 737.
13. S Zhang, C Zhao, S Liu, Y Wang, Y Zhao, et al. (2018) Characteristics and multilineage differentiation of bone marrow mesenchymal stem cells derived from the Tibetan mastiff. Mol Med Rep 18(2): 2097-2109.
14. MM Gabr, MM Zakaria, AF Refaie, SM Khater, SA Ashamallah, et al. (2015) Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells into Insulin-Producing Cells: Evidence for Further Maturation In Vivo. Biomed Res Int 2015: 575837.
15. E Karaoz, A Okcu, ZS Unal, C Subasi, O Saglam, et al. (2013) Adipose tissue-derived mesenchymal stromal cells efficiently differentiate into insulin-producing cells in pancreatic islet microenvironment both in vitro and in vivo. Cytotherapy 15(5): 557-570.
16. L Khorsandi, A Khodadadi, F Nejad-Dehbashi, S Saremy (2015) Three-dimensional differentiation of adipose-derived mesenchymal stem cells into insulin-producing cells. Cell Tissue Res 361(3): 745-753.
17. P Van Pham, P Thi-My Nguyen, A Thai-Quynh Nguyen, V Minh Pham, A Nguyen-Tu Bui, et al. (2014) Improved differentiation of umbilical cord blood-derived mesenchymal stem cells into insulin-producing cells by PDX-1 mRNA transfection, Differentiation 87(5): 200-208.
18. PJ Tsai, HS Wang, YM Shyr, ZC Weng, LC Tai, et al. (2012) Transplantation of insulin-producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats. J Biomed Sci 19(1): 47.
19. QS Guo, MY Zhu, L Wang, XJ Fan, YH Lu, et al. (2012) Combined transfection of the three transcriptional factors, PDX-1, NeuroD1, and MafA, causes differentiation of bone marrow mesenchymal stem cells into insulin-producing cells. Exp Diabetes Res 2012: 672013.
20. ZN Boroujeni, A Aleyasin (2013) Insulin producing cells established using non-integrated lentiviral vector harboring PDX1 gene. World J Stem Cells 5(4): 217-228.
21. T Sapir, K Shternhall, I Meivar-Levy, T Blumenfeld, H Cohen, et al. (2005) Cell-replacement therapy for diabetes: Generating functional insulin-producing tissue from adult human liver cells. Proc Natl Acad Sci U S A 102(22): 7964-7969.
22. A Banga, LV Greder, JR Dutton, JM Slack (2014) Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist. Gene Ther 21(1): 19-27.
23. D Berneman-Zeitouni, K Molakandov, M Elgart, E Mor, A Fornoni, et al. (2014) The temporal and hierarchical control of transcription factors-induced liver to pancreas transdifferentiation. PLoS One 9(2): e87812.
24. HV Do, WT Loke, I Kee, V Liang, SJ David, et al. (2015) Characterization of Insulin-Secreting Porcine Bone Marrow Stromal Cells Ex Vivo and Autologous Cell Therapy In Vivo. Cell Transplant 24(7): 1205-1220.
25. MN Poy, L Eliasson, J Krutzfeldt, S Kuwajima, X Ma, et al. (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432(7014): 226-230.
26. A Jafarian, M Taghikani, S Abroun, A Allahverdi, M Lamei, et al. (2015) The Generation of Insulin Producing Cells from Human Mesenchymal Stem Cells by MiR-375 and Anti-MiR-9. PLoS One 10(6): e0128650.
27. C Bai, Y Gao, X Li, K Wang, H Xiong, et al. (2017) MicroRNAs can effectively induce formation of insulin-producing cells from mesenchymal stem cells. J Tissue Eng Regen Med 11(12): 3457-3468.
28. F Zhao, X Liu, Z Wang, H Lang, T Zhang, et al. (2020) Novel Mouse miRNA Chr13_novelMiR7354-5p Improves Bone-Marrow-Derived Mesenchymal Stem Cell Differentiation into Insulin-Producing Cells. Mol Ther Nucleic Acids 19: 1110-1122.
29. CA Gimenez, M Ielpi, A Mutto, L Grosembacher, P Argibay, et al. (2016) CRISPR-on system for the activation of the endogenous human INS gene. Gene Ther 23(6): 543-547.
30. Z Zhu, QV Li, K Lee, BP Rosen, F Gonzalez, et al. (2016) Genome Editing of Lineage Determinants in Human Pluripotent Stem Cells Reveals Mechanisms of Pancreatic Development and Diabetes. Cell Stem Cell 18(6): 755-768.
31. Y Zhang, Z Dou (2014) Under a nonadherent state, bone marrow mesenchymal stem cells can be efficiently induced into functional islet-like cell clusters to normalize hyperglycemia in mice: a control study. Stem Cell Res Ther 5(3): 66.
32. T Ikemoto, R Feng, M Shimada, Y Saito, S Iwahashi, et al. (2018) A New 2-Step Acceleration Protocol Using a Histone Deacetylase Inhibitor to Generate Insulin-Producing Cells from Adipose-Derived Mesenchymal Stem Cells. Pancreas 47(4): 477-481.
33. H Takeuchi, N Nakatsuji, H Suemori (2014) Endodermal differentiation of human pluripotent stem cells to insulin-producing cells in 3D culture. Sci Rep 4: 4488.